SCHEMBL25865285

SCHEMBL25865285

O=c1oc2ccc(Br)cc2n1CC(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 1/20 0.49
CDYL2 Q8N8U2 1/20 0.49
CDYL Q9Y232 1/20 0.49
CDY1; CDY1B Q9Y6F8 1/20 0.49
SIGMAR1 Q99720 1/20 0.47
NPC1 O15118 1/20 0.46
KMO O15229 2/20 0.45
CD74 P04233 2/20 0.43
MIF P14174 2/20 0.43
IDO1 P14902 4/20 0.42
KMT2A Q03164 3/20 0.41
PTGS2 P35354 1/20 0.40
USP2 O75604 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
MEN1 O00255 2/20 0.39
POLB P06746 1/20 0.39
ASAH1 Q13510 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16932308 0.82 CBX7 (0.50) CBX7CDYL2CDYLCDY1; CDY1BSIGMAR1
SCHEMBL30538007 0.82 CBX7 (0.50) CBX7CDYL2CDYLCDY1; CDY1BSIGMAR1
SCHEMBL16948384 0.82 KMT2A (0.60) NPC1CD74MIFKMT2ATSHR
SCHEMBL16932344 0.82 IDO1 (0.64) KMOIDO1
SCHEMBL616373 0.80 SIGMAR1 (0.53) CBX7CDYL2CDYLCDY1; CDY1BSIGMAR1
SCHEMBL30336433 0.80 SIGMAR1 (0.53) CBX7CDYL2CDYLCDY1; CDY1BSIGMAR1
SCHEMBL16939101 0.79 KMO (0.52) KMOCD74MIFIDO1KMT2A
SCHEMBL20172636 0.78 MIF (0.46) KMOCD74MIFIDO1KMT2A
SCHEMBL30200079 0.78 MAPK1 (0.66) MIFIDO1USP2HPGDTSHR
SCHEMBL782891 0.77 SIGMAR1 (0.57) CBX7CDYL2CDYLCDY1; CDY1BSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B CBX7 1133/4885CDYL2 1702/4885CDYL 2252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.